Sight Sciences Inc
For the period ended Mar 31, 2024. Filed May 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 6, 2024
SGHT$10.75-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(16,269) | $(17,067) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 192 | 146 |
| Accretion of debt discount and amortization of debt issuance costs | 94 | 144 |
| Stock-based compensation expense | 4,506 | 3,523 |
| Provision for credit losses | 36 | (250) |
| Provision for excess and obsolete inventories | (25) | 12 |
| Noncash operating lease expense | 160 | 242 |
| Loss on disposal of property and equipment | — | 66 |
| Noncash loss on extinguishment of debt | 1,033 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,390) | (959) |
| Inventory | 1,003 | (1,036) |
| Prepaid expenses and other current assets | 317 | 593 |
| Other noncurrent assets | 12 | (13) |
| Accounts payable | 371 | 878 |
| Accrued compensation | (501) | (2,394) |
| Accrued and other current liabilities | 2,116 | (1,345) |
| Other noncurrent liabilities | (1,441) | 77 |
| Net cash used in operating activities | (9,786) | (17,383) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (117) | (126) |
| Net cash used in investing activities | (117) | (126) |
| Cash flows from financing activities | ||
| Net proceeds from Hercules Loan Agreement | 34,526 | — |
| Repayment of MidCap Term Loan | (35,375) | — |
| Debt issuance costs | (238) | — |
| Taxes paid on the net share settlement of restricted stock units | — | (205) |
| Proceeds from exercise of common stock options | 145 | 49 |
| Net cash used in financing activities | (942) | (156) |
| Net change in cash and cash equivalents | (10,845) | (17,665) |
| Cash and cash equivalents at beginning of period | 138,129 | 185,000 |
| Cash and cash equivalents at end of period | $127,284 | $167,335 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $1,054 | $1,002 |
| Supplemental noncash disclosure of investing and financing activities | ||
| Acquisition of property and equipment included in accounts payable and accrued liabilities | $— | $10 |
| Common stock warrants issued upon execution of term loan agreement | $609 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.